Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Current Options and Future Directions in Immune Therapy for Glioblastoma.

Lynes J, Sanchez V, Dominah G, Nwankwo A, Nduom E.

Front Oncol. 2018 Dec 5;8:578. doi: 10.3389/fonc.2018.00578. eCollection 2018. Review.

2.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

3.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

4.

Immune Checkpoint in Glioblastoma: Promising and Challenging.

Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, Chen J.

Front Pharmacol. 2017 May 9;8:242. doi: 10.3389/fphar.2017.00242. eCollection 2017. Review.

5.

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.

Ishikawa E, Yamamoto T, Matsumura A.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):321-330. doi: 10.2176/nmc.nmc.ra.2016-0334. Epub 2017 May 24. Review.

6.

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.

PMID:
26454859
7.

Immunosuppressive mechanisms in glioblastoma.

Nduom EK, Weller M, Heimberger AB.

Neuro Oncol. 2015 Nov;17 Suppl 7:vii9-vii14. doi: 10.1093/neuonc/nov151. Review.

8.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
9.

From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?

Madden DL.

Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5. Review.

PMID:
29411148
10.

The progress of immunotherapy for glioblastoma.

Zhou Q, Wang Y, Ma W.

Hum Vaccin Immunother. 2015;11(11):2654-8. doi: 10.1080/21645515.2015.1081727. Review.

11.

A Critical Overview of Targeted Therapies for Glioblastoma.

Jain KK.

Front Oncol. 2018 Oct 15;8:419. doi: 10.3389/fonc.2018.00419. eCollection 2018. Review.

12.

Emerging therapies for glioblastoma.

Thomas AA, Brennan CW, DeAngelis LM, Omuro AM.

JAMA Neurol. 2014 Nov;71(11):1437-44. doi: 10.1001/jamaneurol.2014.1701. Review.

PMID:
25244650
13.

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.

Ning J, Wakimoto H.

Front Microbiol. 2014 Jun 20;5:303. doi: 10.3389/fmicb.2014.00303. eCollection 2014. Review.

14.

Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.

Yeo AT, Charest A.

J Cell Biochem. 2017 Sep;118(9):2516-2527. doi: 10.1002/jcb.25948. Epub 2017 May 3. Review.

15.

Developing immunotherapeutic strategies to target brain tumors.

Lieberman NA, Moyes KW, Crane CA.

Expert Rev Anticancer Ther. 2016 Jul;16(7):775-88. doi: 10.1080/14737140.2016.1192470. Epub 2016 Jun 13. Review.

PMID:
27253692
16.

Combination therapy to checkmate Glioblastoma: clinical challenges and advances.

Ghosh D, Nandi S, Bhattacharjee S.

Clin Transl Med. 2018 Oct 16;7(1):33. doi: 10.1186/s40169-018-0211-8. Review.

17.

Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.

Cuoco JA, Benko MJ, Busch CM, Rogers CM, Prickett JT, Marvin EA.

World Neurosurg. 2018 Dec;120:302-315. doi: 10.1016/j.wneu.2018.08.202. Epub 2018 Sep 6. Review.

PMID:
30196171
18.

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.

Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH.

Front Pharmacol. 2018 Mar 5;9:185. doi: 10.3389/fphar.2018.00185. eCollection 2018. Review.

19.

Engineering challenges for brain tumor immunotherapy.

Lyon JG, Mokarram N, Saxena T, Carroll SL, Bellamkonda RV.

Adv Drug Deliv Rev. 2017 May 15;114:19-32. doi: 10.1016/j.addr.2017.06.006. Epub 2017 Jun 15. Review.

20.

Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.

Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM.

Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19. Review.

PMID:
29145974

Supplemental Content

Support Center